Clinical trial
Topical Alprostadil for Female Sexual Arousal Disorder
NCT00324948 · VIVUS LLC, Industry · Completed
Key facts
| NCT number | NCT00324948 |
|---|---|
| Title | Topical Alprostadil for Female Sexual Arousal Disorder |
| Official title | A Double-Blind, Randomized, 6-Month Evaluation of the Safety and Efficacy of Topical Alprostadil in Hysterectomized Women With Female Sexual Arousal Disorder (FSAD) |
| Lead sponsor | VIVUS LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sexual Dysfunction, Physiological |
| Intervention type | Drug |
| Interventions | Topical alprostadil (PGE-1) |
| Enrollment | 300 |
| Start date | Sep 1, 2004 |
| Primary completion | Aug 1, 2006 |
| Completion | Nov 1, 2006 |
| First posted | May 11, 2006 |
| Last update posted | Mar 10, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: